



# Aiming for Japan to Become Indispensable to Global Ecosystem for Innovative Drug Discovery

～The “Five Roles” Expected of “Public-Private Council” for the Second Opening of the Country～

Masato Iwasaki

July 30, 2024

# The “Five Roles” Expected of Public-Private Councils

Public and private sectors collaborate to create an innovative drug discovery to attract foreign countries through growth industry policies in pharmaceuticals and healthcare

**Confirming and accelerating the progress of each measure of the strategy as a “public-private council” for the second opening of the country**

Ministry of Health, Labor and Welfare and other related ministries



Experienced pharmaceutical companies, VC, academia, and startups with a global market presence



## (1) Intelligence

Assessing the current situation based on the latest information

- Pharmaceutical affairs law (optimized by including the perspectives of overseas stakeholders)
- Understanding the changing global drug discovery environment
  - Start-up
  - Investment from VC and others
- Unmet medical needs



## (2) Investment optimization

Evaluating and optimizing limited investment allocations based on achievement of KPIs

- Seeds Search
- Early Stage Clinical Trials
- VC (Venture Creation Model)
- CDMOs that can handle new technologies



## (3) Attracting foreign capital

Lobbying foreign capital for a “second opening of the country”

- Overseas VC
- Overseas pharmaceutical companies
- Globalization of certified VC



## (4) Human resource and organizational development

Developing human resources and organizations capable of global expansion

- Entrepreneurship
- Management
- Business strategy planning including overseas markets
- Exit strategies (expertise in M&A/IPO)




## (5) Dissemination to foreign countries and the public


Communicating “seriousness, attractiveness, and importance” of drug discovery

- Familiarization with the pharmaceutical affairs law
- Support measures for Asia
- Startup support
- VC support
- Drug lag and loss prevention measures
- Rare disease initiatives

## 【Reference Material 1-1】 The Current “Global Ecosystem for Innovative Drug Discovery” and Japan



# 【Reference Material 1-2】 Japan's Presence as a Member of the Global Ecosystem for Innovative Drug Discovery




**Becoming an integral part of the global innovative drug discovery, including Asia**

# 【Reference Material 2】 Division of Roles and Collaboration between Public and Private Sectors at Each Stage

## ■Stages of the Drug Discovery Value Chain



## ■Division of Roles and Collaboration between Public and Private Sectors at Each Stage



**These will be “optimized” by the five roles of public-private councils**